BGI is committed to continued genomics and diagnostics education both internally and outside
of the organization. The company regularly conducts studies, holds webinars, contributes to
publications and invests in research initiatives in an effort to provide clear and informative
information for businesses and individuals looking to gain knowledge on the latest technologies
in the in vitro diagnostics space.
BGI Published Data
BGI is honored to have been included in the FDA’s Comparative Study for SARS-CoV-2
Reference Panel. The study certified the comparative performance of BGI’s RT-PCR kit for
SARS-CoV-2 detection among other emergency use authorized tests and demonstrated that
the kit is one of the most sensitive for detecting SARS-CoV-2 collected by swabs in transport
media. The kit was also designated as one of the earliest IVD kits listed in the World Health
Organization’s (WHO) Emergency Use Listing (EUL) for detecting SARS-CoV-2.
In addition, a Nature Biotech article on BGI’s collaboration with The Francis Crick Institute in
the United Kingdom touts BGI’s PCR as “adequate sensitivity for current clinical algorithms, in
which testing for symptomatic healthcare workers is performed within a specific timeframe.”
Another Nature Methods article cites an interview with the chief scientist of infectious disease
at BGI Research for his expert opinions in the applications of RT-PCR tests and sequencing-based
kits in COVID-19 diagnostics.